Cancer clinical trials最新文献

{"title":"Metabolic Kidney Cancer Disease","authors":"Aref Salah","doi":"10.37421/2577-0535.2021.6.E118","DOIUrl":"https://doi.org/10.37421/2577-0535.2021.6.E118","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"45 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70053358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brain Tumor Therapy","authors":"Alisa Madasamy","doi":"10.37421/2577-0535.2021.6.E115","DOIUrl":"https://doi.org/10.37421/2577-0535.2021.6.E115","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"6 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70053341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Therapies","authors":"E. Shen","doi":"10.37421/2577-0535.2021.6.E114","DOIUrl":"https://doi.org/10.37421/2577-0535.2021.6.E114","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"6 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70053284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge, Attitude and Practice of Indian Oncology Residents on Clinical Trials: An Observational Study","authors":"R. Cs, M. Ponraj, P. Jogmaya, Dhanraju Km, N. Jadav, Jagdeep Singh, S. Kayal, B. Dubashi, S. Cyriac","doi":"10.37421/2577-0535.2020.5.53","DOIUrl":"https://doi.org/10.37421/2577-0535.2020.5.53","url":null,"abstract":"Background and objectives: A limiting factor in cancer treatment and prevention has been an inadequate accrual of patients onto clinical trials this more so in India and developing countries may be because of majority of trials will be done as dissertation of an oncology fellow. Many oncology training institutions are not having training curriculum regarding clinical trial design and basic statistical training which are barriers for accrual of patient in trials. Therefore, we aimed to assess the knowledge, attitude and practice of oncology residents on clinical trials across the country to improve the curriculum methodology so that we can produce better data on clinical trials. Methods: A total 50 students were recruited across the country; students were interviewed either directly or through telephonic conversation. Minimum criteria to enroll in the study was to have at least 1 year of working knowledge in oncology institute (only senior residents were included).Verbal informed consent was obtained from all the study participants. Results: All residents participated in the study know that clinical research is imperative, however only 30 (60%) of them showed interest towards cancer clinical trials. Thirty (60%) of the participants depending on western data for their patient management.36 (73%) participants felt that they were not able to interpret the data given in clinical trials. Only 6 (11%) of the participants had access to all cancer related journals. Though 35 (70%) of the participants discuss published clinical trials every week, only 25 (50%) of the residents are changing their decision based on clinical trial data during their patient management. Conclusions: In our study it was found that the resident doctors felt that clinical research is imperative in delivering appropriate management in malignant diseases. However, they had displeasing knowledge on health research. They have positive attitude towards cancer research, but they are failing to implement due to lack of training curriculum.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"5 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70052948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primitive Neuroectodermal Tumor (PNET) of the Parotid Gland in a 13-year-old Female: A Rare Case Report","authors":"Ait Taleb Oum’h, Hajar, M. Noureddine, Belhaj Najoua, N. Sophia, Bencheikh Razika, A. BenbouzidM, OujilalAbdelilah, Essakalli Leila","doi":"10.37421/2577-0535.2020.5.47","DOIUrl":"https://doi.org/10.37421/2577-0535.2020.5.47","url":null,"abstract":"Primitive neuroectodermal tumor (PNET) belongs to the Ewing family of tumors. It’s a rare and highly malignant small round cell tumor that generally occurs in adolescents and young adults. Its location at the parotid gland is extremely unusual. Here we describe a rare case of 13-year-old female who presented with painful, progressively enlarging and swelling mass located in the right parotid gland.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"5 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70052816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Presentation and Management of Osteosarcoma","authors":"T. Belhocine","doi":"10.37421/2577-0535.2020.5.51","DOIUrl":"https://doi.org/10.37421/2577-0535.2020.5.51","url":null,"abstract":"Osteosarcoma (OS) is the commonest sort of primary solid tumor that develops in bone. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the result for those patients with metastatic or recurrent OS remains dismally poor and, therefore, novel agents and treatment regimens are urgently required. A hypothesis to elucidate the resistance of OS to chemotherapy is that the existence of drug resistant CSCs with progenitor properties that are responsible of tumor relapses and metastasis.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"5 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70052885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review Study on Vaping and Status of Vaping in India","authors":"Vipin Thampi, R. Nair, R. Rawat, Aman Makhaik, Subhojit Dey","doi":"10.20944/PREPRINTS201808.0380.V1","DOIUrl":"https://doi.org/10.20944/PREPRINTS201808.0380.V1","url":null,"abstract":"Introduction-Electronic Cigarettes(E-cigarettes) was introduced into the market in 2007 as an alternative method for quitting smoking. Considering the global rise in the use of Electronic cigarettes, the study aims to perform the comprehensive review of literature on E -Cigarettes. Objectives-To explore the Presence and usage of E-cigarettes in India, to determine the Health -related issues due to the use of E- cigarettes globally, To compare conventional smoking modalities with E- cigarette usage globally, To assess whether use of E-Cigarettes can be helpful in reduction of behavior related to smoking cigarettes Methods -The Literature Search Strategy was developed using the key words based on the objectives and the electronic based data source for identification of papers was done in PubMed and Research Gate. The Study was Conducted from December 2017 to March 2018. Results -There are almost 75 companies which are supplying E-Cigarettes through online in India, and there is no brand in India which manufactures its own product except Evolve Vapors. Limited Studies assessing the health effects of E-cigarettes have been performed as most of them are done in the laboratory conditions. The use of E -Cigarettes were more in current smokers as the usage increasing in adolescents because of the modifiability and similarity with the Conventional Cigarettes. Randomized Control Trial(RCT) and Cohort Study were not able to generate enough evidence because of the Smaller no of participants in the study and lack of previous data available Conclusion-Well designed Newer Generation E -cigarettes trials must be monitored and measured for a longer period so that the Safety and efficacy of the device can be generated.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"03 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43224836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Cutaneous Apocrine Carcinoma with Distant Metastasis","authors":"Titou Hicham, Boui Mohammed, Hjira Naoufal","doi":"10.4172/2577-0535.1000145","DOIUrl":"https://doi.org/10.4172/2577-0535.1000145","url":null,"abstract":"Introduction: Cutaneous apocrine carcinomas (CAC) are rare adnexal malignant tumors preferentially localized in the axillary and anogenital regions. They are characterized by mammillated plaques or asymptomatic nodules and present a differential diagnosis problem with cutaneous metastases of breast adenocarcinoma. Metastatic CACs are a therapeutic challenge. Case presentation: A 63-years-old man, chronic smoker, presented with painless left axillary mammillated plaques that had been slowly evolving for 18 months. Clinical examination found a tumor mass associated with magma of left axillary lymph nodes. Histological study and immunohistochemical staining of the skin evoked the diagnosis of cutaneous metastasis of breast adenocarcinoma. However, the diagnosis of axillary CAC was retained owing to the negativity of explorations in search of a primitive adenocarcinoma and the slow clinical course. Morphological assessment showed lymph node, hepatic and pulmonary metastases. Surgical excision with lymph node dissection was performed followed by chemotherapy. Discussion: Metastatic CACs are rare. Sometimes, the existence of misleading tumor architecture and nonspecific nature of the immunolabeling explain the difficulty of the differential histological diagnosis between axillary CAC and cutaneous metastasis of lobular breast adenocarcinoma. Because of the rarity of this neoplasia no effective treatment is currently established. Conclusion: We report a new case of metastatic axillary CAC. This case illustrates the importance of anatomoclinical correlation in cutaneous oncology and highlighted the need of treatment outcome evaluations of other cases of metastatic CAC to offer optimal treatment.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"03 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2577-0535.1000145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine Therapy in Epithelial Ovarian Cancer (EOC) New Insights in an Old Target: A Mini Review","authors":"A. Knipprath-Mészáros, V. Heinzelmann-Schwarz, M. Vetter","doi":"10.4172/2577-0535.1000144","DOIUrl":"https://doi.org/10.4172/2577-0535.1000144","url":null,"abstract":"Introduction: Endocrine therapy with tamoxifen and aromatase inhibitors has been used in Estrogen Receptor (ER) positive breast cancer for decades. Epithelial ovarian cancer, in particular serous Low- and High Grade Subtypes (LGSOC, HGSOC), shows a similar high ER expression and represents therefore a potential target for endocrine therapy. Many treatments have been evaluated in phase II clinical trials in heavily pretended patients, but the overall tumor response and agent superiority (tamoxifen vs. aromatase inhibitors) remains unclear. Methods: We present a literature review of endocrine therapy for ovarian cancer and emphasize the role of endocrine maintenance therapy with letrozole after standard of care. Results: Endocrine therapy appears to be an eligible and cost effective treatment option with good quality of life in the adjuvant and recurrent treatment of advanced ovarian cancer. The trend shows the highest effect in histological subtypes with the highest ER expression (LGSOC and HGSOC).","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"03 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2577-0535.1000144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pleomorphic Sarcoma of Larynx: A Case Report","authors":"N. Mahiou","doi":"10.4172/2577-0535.1000146","DOIUrl":"https://doi.org/10.4172/2577-0535.1000146","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"03 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}